Efficacy News and Research

RSS

Study demonstrates efficacy of canakinumab at tapering corticosteroid use in patients with SJIA

Study findings first presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate the efficacy of canakinumab at tapering corticosteroid (CS) use in patients with SJIA.

14 Jun 2013

Study provides new insight into how pyrazinamide works

Pyrazinamide (PZA)-a frontline tuberculosis drug-kills dormant persister bacteria and plays a critical role in shortening TB therapy. PZA is used for treating both drug susceptible and multi-drug resistant TB but resistance to PZA occurs frequently and can compromise treatment.

14 Jun 2013

Penn Medicine researchers identify key molecular player in recurrent breast cancer

According to the American Cancer Society, nearly 40,000 women in the United States will succumb to breast cancer this year. Most of these women will die not from the primary tumor but rather tumor recurrence - the reappearance of the disease following treatment.

14 Jun 2013

PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4 billion) Series C financing.

13 Jun 2013

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Arthritis (pcJIA).

13 Jun 2013

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA).

13 Jun 2013

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

New PSUMMIT 2 data first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis (PsA).

13 Jun 2013

Combination of Pressure Right and antiemetic drug therapy can reduce PONV with no adverse effects

From a clinical-based perspective, postoperative nausea and vomiting (PONV) can be characterized as an unmet global phenomenon in which anesthesia practitioners and PACU nurses worldwide are seeking more efficient clinical strategies for preventing PONV.

13 Jun 2013

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks.

13 Jun 2013

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrates the efficacy of the ARASHI method at evaluating radiographic (X-ray) joint damage in RA.

13 Jun 2013

Questions emerge as dust settles surrounding Plan B policy change

News outlets offer day-after coverage of the Obama administration's reversal on the morning-after contraceptive pill.

13 Jun 2013

WHO issues interim policy guidance on inclusion of bedaquiline to treat adults with MDR-TB

WHO estimates that up to half a million new cases of multidrug-resistant tuberculosis occur worldwide, each year. Current treatment regimens for MDR-TB present many challenges: treatment lasts 20 months or more, requiring daily administration of drugs that are more toxic, less effective, and far more expensive than those used to treat drug-susceptible TB.

13 Jun 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

New data from Boehringer Ingelheim’s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV),1 one of the most common types of HCV globally.2

13 Jun 2013

One-third of RA patients discontinue therapy within the first year of treatment

Data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, show that up to one-third of rheumatoid arthritis patients discontinue or change therapy within the first year of treatment.

13 Jun 2013

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

Before we talk about p53, it is important to understand why cancer cells are a problem for the body. Cancer cells multiply recklessly, refuse to die and blithely metastasize to set up shop in places where they don’t belong.

12 Jun 2013

Neuromodulators provide guidelines for implantation of "digital drugs" to manage chronic pain

Neuromodulators have joined together in the Neuromodulation Appropriateness Consensus Committee (NACC) to provide the first coordinated set of recommendations about patient selection and appropriateness for implantation of "digital drugs" to manage chronic pain.

12 Jun 2013

Johns Hopkins researchers develop experimental vaccine for TB meningitis

A team of Johns Hopkins researchers working with animals has developed a vaccine that prevents the virulent TB bacterium from invading the brain and causing the highly lethal condition TB meningitis, a disease that disproportionately occurs in TB-infected children and in adults with compromised immune system.

12 Jun 2013

Efficacy News and Research

Study demonstrates efficacy of canakinumab at tapering corticosteroid use in patients with SJIA

Study provides new insight into how pyrazinamide works

Penn Medicine researchers identify key molecular player in recurrent breast cancer

PRISM Pharma announces closing of $15 million Series C financing

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Combination of Pressure Right and antiemetic drug therapy can reduce PONV with no adverse effects

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Study demonstrates efficacy of ARASHI method at evaluating radiographic joint damage in RA

Questions emerge as dust settles surrounding Plan B policy change

WHO issues interim policy guidance on inclusion of bedaquiline to treat adults with MDR-TB

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

One-third of RA patients discontinue therapy within the first year of treatment

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

Neuromodulators provide guidelines for implantation of "digital drugs" to manage chronic pain

Johns Hopkins researchers develop experimental vaccine for TB meningitis

Cerus enrolls patient in two European clinical trials for INTERCEPT System for RBCs

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

Abbott starts ABSORB Japan trial to evaluate Absorb BVS in patients with CAD

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News